ALLMedicine™ Hepatocellular Carcinoma Center

Aug 1st, 2021 - EGFR inhibition and lenvatinib exhibit synthetic lethality in hepatocellular carcinoma.

Aug 1st, 2021 - Sarcomatoid hepatocellular carcinoma (HCC) is a rare and highly lethal histological subtype of HCC, with completely unknown genetic etiology and therapeutic targets. We included 16 patients with sarcomatoid HCC receiving radical resection among 67...

Aug 1st, 2021 - Minimally invasive approaches are increasingly being applied in surgeries and have recently been used in living donor hepatectomy. We have developed a safe and reproducible method for minimally invasive living donor liver transplantation, which co...

Jul 31st, 2021 - Chronic hepatitis B (CHB) infection remains the most frequent etiology of hepatocellular carcinoma globally as well as a major cause of cirrhosis. Despite vaccination, substantial numbers of persons have already been infected with hepatitis B viru...

Jul 31st, 2021 - With the increasing incidence of obesity and metabolic syndrome worldwide, concomitant nonalcoholic fatty liver disease (NAFLD) in patients with chronic hepatitis B (CHB) has become highly prevalent. The risk of dual etiologies, outcome, and mecha...

Mar 30th, 2021 - This document is a summary of the French Intergroup guidelines regarding the management of hepatocellular carcinoma (HCC) published in March 2019. It is a collaborative work under the auspices of most of the French medical societies involved in th...

Dec 12th, 2020 - Nonalcoholic fatty liver disease (NAFLD) is a leading cause of chronic liver disease, with global public health impact affecting more than 25% of the global population. NAFLD is associated with significant morbidity and mortality from cirrhosis, h...

Oct 9th, 2020 - Non-alcoholic fatty liver disease (NAFLD) currently represents an epidemic worldwide. NAFLD is the most frequently diagnosed chronic liver disease, affecting 20-30% of the general population. Furthermore, its prevalence is predicted to increase ex...

Feb 19th, 2020 - The most recent version of the European Society for Medical Oncology (ESMO) Clinical Practice Guidelines for the diagnosis, treatment and follow-up of hepatocellular carcinoma (HCC) was published in 2018, and covered the diagnosis, management, tre...

Jul 16th, 2019 - The purpose of this clinical practice update is to define key principles in the surveillance of hepatobiliary cancers including cholangiocarcinoma, gallbladder adenocarcinoma, and hepatocellular carcinoma in patients with primary sclerosing cholan...

May 6th, 2020 - Observational study to evaluate, under real-world practice conditions, the safety and effectiveness of regorafenib in patients diagnosed with unresectable hepatocellular carcinoma (uHCC)

May 1st, 2020 - This is a pilot single arm study with the primary endpoints of feasibility and preliminary estimates of safety and efficacy. This protocol builds on over 25 years of experience with high dose liver RT (Radiation Therapy), and in particular adaptiv...

Apr 29th, 2020 - 1.1 Primary Objective & Hypothesis Determine the safety and tolerability of SBRT followed by nivolumab or ipilimumab with nivolumab for hepatocellular carcinoma by establishing the rates of toxicity that occur within 6 months from start of SBRT. H...

Apr 24th, 2020 - Human oral cavity is a great habitat for more than 600 species of bacteria, known as oral microbiota, living in equilibrium. Oral microbiota plays an important role in maintaining oral health; however when the balance in oral bacterial population ...

Apr 24th, 2020 - The main purpose of this study is to evaluate the safety, tolerability, and efficacy of the study drug known as galunisertib in combination with nivolumab in participants with advanced refractory solid tumors and in recurrent or refractory non-sma...

Jul 20th, 2021 - NEW YORK (Reuters Health) - New research provides supporting evidence for chemopreventive effects of statins on hepatocellular carcinoma (HCC) in patients with nonalcoholic steatohepatitis (NASH) cirrhosis. In the American Journal of Gastroenterol...

Jul 19th, 2021 - Patients with hepatocellular carcinoma (HCC) can be offered transarterial radioembolization (TARE) as a safe and effective first-line treatment or adjunct to other locoregional therapies, authors of a large multicenter study reported. Among 422 pa...

Jul 15th, 2021 - NEW YORK (Reuters Health) - Donafenib, a novel multikinase inhibitor and a deuterated sorafenib derivative, significantly improved overall survival versus sorafenib in first-line treatment of patients with advanced hepatocellular carcinoma (HCC) i...

Jul 8th, 2021 - Stopping nucleoside analog therapy in patients with hepatitis B viral (HBV) infections results in sustained viral suppression in only a minority of patients, but a new study suggests there are immune signatures that may serve as predictive biomark...

Jul 6th, 2021 - With the novel immunotherapy tislelizumab, durable responses are achieved for patients with advanced hepatocellular carcinoma (HCC), regardless of the number of prior lines of therapy, show results from a phase 2, open-label trial. RATIONALE 208 i...